Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes

Clinical Therapeutics

Volumn 35, Issue 3, 2013, Pages

  Zambrowicz, Brian ^a   Ding, Zhi Ming ^a   Ogbaa, Ike ^a   Frazier, Kenny ^a   Banks, Phillip ^a   Turnage, Anne ^a   Freiman, Joel ^a   Smith, Melinda ^a   Ruff, Dennis ^b   Sands, Arthur ^a   Powell, David ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

^b Icon Development Solutions   (United States)

Author keywords

Adult; Diabetes; Dipeptidyl peptidase 4; GIP; GLP 1; Glucose; Glycemic control; Human; Insulin; PYY; SGLT1; SGLT2; Sitagliptin; Urinary glucose excretion

Indexed keywords

ANTIDIABETIC AGENT; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LX 4211; METFORMIN; PEPTIDE YY; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; C57BL 6 MOUSE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; MALE; MONOTHERAPY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; URINALYSIS;

EID: 84874977086     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.01.010     Document Type: Article

References (64)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
2. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865. UK Prospective Diabetes Study (UKPDS) Group.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
5. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
6. Ray K.K., Seshasai S.R., Wijesuriya S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373:1765-1772.
7. Huang E.S., Basu A., O'Grady M., Capretta J.C. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care 2009, 32:2225-2229.
8. 2011 International Diabetes Federation International Diabetes Federation (IDF), Brussels, Belgium, IDF Diabetes Atlas, 5th ed., Accessed December 13, 2012. http://www.idf.org/diabetesatlas.
9. Farag Y.M., Gaballa M.R. Diabesity: an overview of a rising epidemic. Nephrol Dial Transplant 2011, 26:28-35.
10. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors. Jama 2003, 289:76-79.
11. Shamseddeen H., Getty J.Z., Hamdallah I.N., Ali M.R. Epidemiology and economic impact of obesity and type 2 diabetes. Surg Clin North Am 2011, 91:1163-1172. vii.
12. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
13. Wallace T.M., Matthews D.R. Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes. Diabet Med 2002, 19:465-469.
14. Fonseca V.A. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009, 32(Suppl):S151-S156.
15. Rodbard H.M., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
16. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009, 52:17-30.
17. Wright E.M., Loo D.D., Hirayama B.A. Biology of human sodium glucose transporters. Physiol Rev 2011, 91:733-794.
18. Zambrowicz B., Freiman J., Brown P.M., et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012, 92:158-169.
19. Parker H.E., Reimann F., Gribble F.M. Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev Mol Med 2010, 12:e1.
20. Shibazaki T., Tomae M., Ishikawa-Takemura Y., et al. KGA-2727, a novel selective inhibitor of high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2012, 342:288-296.
21. Rubino F., Moo T.A., Rosen D.J., Dakin G.F., Pomp A. Diabetes surgery: a new approach to an old disease. Diabetes Care 2009, 32(Suppl 2):S368-S372.
22. Vetter M.L., Cardillo S., Rickels M.R., Iqbal N. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med 2009, 150:94-103.
23. Pournaras D.J., Osbourne A., Hawkins S.C., et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg 2010, 252:966-971.
24. Cummings D.E. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond) 2009, 33(Suppl 1):S33-S40.
25. Tarini J., Wolever T.M. The fermentable fibre inulin increases postprandial serum short-chain fatty acids and reduces free-fatty acids and ghrelin in healthy subjects. Appl Physiol Nutr Metab 2010, 35:9-16.
26. Zhou J., Martin R.J., Tulley R.T., et al. Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am J Physiol Endocrinol Metab 2008, 295:E1160-E1166.
27. Nilsson A.C., Ostman E.M., Holst J.J., Bjorck I.M. Including indigestible carbohydrates in the evening meal of healthy subjects improves glucose tolerance, lowers inflammatory markers, and increases satiety after a subsequent standardized breakfast. J Nutr 2008, 138:732-739.
28. Kim W., Egan J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008, 60:470-512.
29. Ahren B. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes 2010, 3:31-41.
30. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
31. Seino Y., Fukrushima M., Yabe D. GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig 2010, 1:8-23.
32. Meier J.J., Gallwitz B., Siepmann N., et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003, 46:798-801.
33. Cheng V., Kashyap S.R. Weight considerations in pharmacotherapy for type 2 diabetes. J Obes 2010 Sep 19, [Epub ahead of print].
34. Brommage R., Desai U., Revelli J.P., et al. High-throughput screening of mouse knockout lines identifies true lean and obese phenotypes. Obesity (Silver Spring) 2008, 16:2362-2367.
35. RosenstockJ,ZambrowiczB,Lapuerta P, et al. Impact of LX4211, a dual inhibitor of sodium glucose transporter 1 and 2 on cardiovascular risk factors in type 2 diabetes. Abstract presented at: 2012 American Heart Association annual meeting, November 3-7, 2012, Los Angeles, Calif.
36. Charbonnel B., Karasik A., Liu J., Wu M., Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2638-2663.
37. Goldstein B.J., Feinglos M.N., Lunceford J.K., et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30:1979-1987.
38. Williams-Herman D., Johnson J., Teng R., et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009, 25:569-583.
39. Williams-Herman D., Johnson J., Teng R., et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12:442-451.
40. Reasner C., Olansky L., Seck T.L., et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011, 13:644-652.
41. Migoya E.M., Bergeron R., Miller J.L., et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010, 88:801-808.
42. Tahrani A.A., Bailey C.J., Del Pratto S., Barnett A.H. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011, 378:182-197.
43. Gage D. Weight loss/maintenance as an effective tool for controlling type 2 diabetes: novel methodology to sustain weight reduction. Diabetes Metab Res Rev 2012, 28:214-218.
44. Igel L.I., Powell A.G., Apovian C.M., Aronne L.I. Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus. Curr Atheroscler Rep 2012, 14:60-69.
45. Meneghini L.F., Orozco-Beltran D., Khunti K., et al. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 2011, 96:3337-3353.
46. Xiong Y., Miyamoto N., Shibata K., et al. Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc Natl Acad Sci U S A 2004, 101:1045-1050.
47. Roelofsen H.M., Priebe M.G., Vonk R.J. The interaction of short-chain fatty acids with adipose tissue: relevance for prevention of type 2 diabetes. Benef Microbes 2010, 1:433-437.
48. Freeland K.R., Wolever T.M. Acute effects of intravenous and rectal acetate on glucagon-like peptide-1, peptide YY, ghrelin, adiponectin and tumour necrosis factor-alpha. Br J Nutr 2010, 103:460-466.
49. Karra E., Chandarana K., Batterham R.L. The role of peptide YY in appetite regulation and obesity. J Physiol 2009, 587:19-25.
50. Moriya R., Shirakura T., Ito J., et al. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab 2009, 297:E1358-E1365.
51. Gorboulev A., Schürmann A., Vallon V., et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 2012, 61:187-196.
52. Bloomgarden Z.T. Incretin concepts. Diabetes Care 2010, 33:e20-e25.
53. Holmes G.M., Browning K.N., Tong M., et al. Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions. J Physiol 2009, 587:4749-4759.
54. Koda S., Date Y., Murakami N., et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 2005, 146:2369-2375.
55. Ruttimann E.B., Arnold M., Hillebrand J.J., et al. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009, 150:1174-1181.
56. Abbott C.R., Monteiro M., Small C.J., et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 2005, 1044:127-131.
57. Balkan B., Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1449-R1454.
58. Wan S., Coleman F.H., Travagli R.A. Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons. Am J Physiol Gastrointest Liver Physiol 2007, 292:G1474-G1482.
59. Ahren B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am J Physiol Regul Integr Comp Physiol 2004, 286:R269-R272.
60. Plamboeck Am Veedfald S, Deacon C, et al. The effect of glp-1 on food intake is lost in truncal vagotomized subjects. Abstract presented at 2012 American Diabetes Association annual meeting, June 8-12, 2012; Philadelphia, Pa.
61. Fushiki T., Kojima A., Imoto T., et al. An extract of Gymnema sylvestre leaves and purified gymnemic acid inhibits glucose-stimulated gastric inhibitory peptide secretion in rats. J Nutr 1992, 122:2367-2373.
62. Miyawaki K., Yamada Y., Ban N., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002, 8:738-742.
63. Chao E.C., Henry R.R. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010, 9:551-559.
64. Washburn W.N. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opin Ther Pat 2009, 9:1485-1499.